Socinski MA, Stinchcombe TE, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Khandani A, Morris DE. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial. J Clin Oncol. 2012;30(32):3953-3959.

Kilburn JM, Kuremsky JG, Blackstock AW, Kearns WT, Hampton CJ, Hinson WH, Miller AA, Petty WJ, Urbanic JJ. Thoracic reirradiation in patients with stereotactic body radiation therapy (SBRT) as first or second course of treatment [abstract]. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S604.

Kuremsky JG, Petty WJ, Miller A, Hinson WH, Hampton CJ, Blackstock AW, Urbanic JJ. Hypofractionated radiation therapy for stage I and II non-small cell lung cancer [abstract]. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S153-S154.

Stinchcombe T, Socinski MA, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Morris DE. Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2011;29(Suppl):abstr 7016.

Ruiz J, Chou J, Geisinger KR, Schoppe CH, Miller AA, Willingham MC, Petty WJ, Bolemon BH, Miller LD. Microarray gene expression patterns recapitulated on a clinically tractable diagnostic platform using breast and lung cancer formalin-fixed paraffin-embedded tissues [abstract]. J Clin Oncol. 2011;29(Suppl):e21027.

Waller LL, Miller AA, Streer NP, Lovato JF, Petty WJ. Phase II study of dose-dense chemotherapy followed by dose-intense erlotinib for initial treatment of metastatic NSCLC [abstract]. J Clin Oncol. 2011;29(Suppl):abstr 7601.

Petty WJ, Voelzke WR, Urbanic JJ, Varela VA, Waller LL, Swift CB, Graham RM, Memoli VA, Dragnev KH. High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer. Lung Cancer. 2011;74(3):384-391.

Petty WJ, Varela VA, Swift CB, Urbanic JJ. A role for angiotensin converting enzyme inhibition in lung cancer chemoprevention [abstract]. Int J Mol Med. 2011;28(Suppl 1):S68.

Kuremsky JG, Urbanic JJ, Petty WJ, Lovato JF, Bourland JD, Tatter SB, Ellis TL, McMullen KP, Shaw EG, Chan MD. Tumor histology predicts patterns of failure and survival in patients with lung cancer treated with gamma knife radiosurgery [abstract]. Int J Radiat Oncol Biol Phys. 2011;81(2 Suppl):S595.

Center B, Petty WJ, Ayala D, Hinson WH, Lovato J, Capellari J [sic] [Cappellari J], Oaks T, Miller AA, Blackstock AW. A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. J Thorac Oncol. 2010;5(1):69-74.

Waller LL, Miller AA, Petty WJ. Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke. Lung Cancer. 2010;67(1):12-16.

Waller LL, Weaver KE, Petty WJ, Miller AA. Effects of continued tobacco use during treatment of lung cancer. Expert Rev Anticancer Ther. 2010;10(10):1569-1575.

Waller LL, Miller AA, Streer NP, McCoy TP, Petty WJ. Overcoming pharmacokinetic resistance to erlotinib: rationale and preliminary findings from a phase II study [abstract]. J Thorac Oncol. 2010;5(6 Suppl 3):S247-S248.

Ruiz J, Miller AA, Petty WJ, Chou JW, Miller LD. A novel prognostic transcriptional signature for early stage non-small cell lung cancer [abstract]. J Thorac Oncol. 2010;5(12 Suppl 7):S505.

Petty WJ, Miller AA, Aklilu M, McCoy TP, Swift CB, Torti FM. The tumor tissue renin-angiotensin system as a target for cancer therapy [abstract]. Int J Mol Med. 2010;26(Suppl 1):S19.

Hughes AN, O'Brien MER, Petty WJ, Chick JB, Rankin E, Woll PJ, Dunlop D, Nicolson M, Boinpally R, Wolf J, et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol. 2009;27(8):1220-1226.

Soto-Pantoja DR, Petty WJ, Gallagher PE, Tallant EA. Angiotensin-(1-7) inhibits triple negative tumor growth through the inhibition of angiogenesis and a reduction in placental growth factor PIGF [abstract]. Cancer Res. 2009;69(2 Suppl):103S.

Socinski MA, Stinchcombe TE, Halle JS, Moore DT, Petty WJ, Blackstock AW, Gettinger SN, Decker RH, Khandani AH, Morris DE. Incorporation of bevacizumab (B) and erlotinib (Er) with induction (I) and concurrent (C) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC) [abstract]. J Thorac Oncol. 2009;4(9 Suppl 1):S372-S373.

Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res. 2009;15(23):7398-7404.

Swift CB, Varela VA, Graves JT, Dmitrovsky E, Petty WJ. Comparison of expression and function of two functional RARbeta isoforms in human cancer: clinical implications for the differential splicing of the RARbeta gene [abstract]. Mol Cancer Ther. 2009;8(12 Suppl 1):A208.

Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Phase I study of angiotensin-(1-7), an endogenous antiangiogenic hormone: clinical, pharmacokinetic, and biomarker findings [abstract]. Mol Cancer Ther. 2009;8(12 Suppl 1):B208.

Socinski MA, Stinchcombe TE, Halle JS, Moore DT, Petty WJ, Blackstock AW, Gettinger SN, Decker RH, Khandani AH, Morris DE. Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2009;27(15 Suppl):7528.

Swift CB, Hays JL, Petty WJ. Distinct functions of retinoic acid receptor beta isoforms: implications for targeted therapy. Endocr Metab Immune Disord Drug Targets. 2008;8(1):47-50.

Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Bi-directional translational research with angiotensin-(1-7) uncovers placental growth factor as a therapeutic target [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research ; 2008 Apr 12-16; San Diego (CA). Philadelphia (PA): AACR. 2008;():Abstr 4968.

Voelzke WR, Petty WJ, Lesser GJ. Targeting the epidermal growth factor receptor in high-grade astrocytomas. Curr Treat Options Oncol. 2008;9(1):23-31.

Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Phase I trial of angiotensin-(1-7): an endogenous anti-angiogenic hormone [abstract]. J Clin Oncol. 2008;26(15 Suppl):634s.

Socinski MA, Morris DE, Stinchcombe TE, Halle JS, Moore DT, Tynan MT, Siegel MA, Petty WJ, Blackstock AW, Khandani AH, et al. Incorporation of bevacizumab (B) and erlotinib (Er) with induction (I) and concurrent (C) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2008;26(15 Suppl):401s.

Petty WJ, Hughes AN, O'Brien MER, Chick JB, Rankin E, Woll P, Dunlop D, Nicolson M, Boinpally R, Price A. Overcoming a CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers--pharmacokinetic and exploratory survival analyses in patients with advanced non-small cell lung cancer [abstract]. J Thorac Oncol. 2008;3(11 Suppl 4):S279.

Yuan Z, Goetz JA, Singh S, Ogden SK, Petty WJ, Black CC, Memoli VA, Dmitrovsky E, Robbins DJ. Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Oncogene. 2007;26(7):1046-1055.

Dragnev KH, Petty WJ, Shah SJ, Lewis LD, Black CC, Memoli V, Nugent WC, Hermann T, Negro-Vilar A, Rigas JR, et al. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res. 2007;13(6):1794-1800.

Petty WJ, Knight SN, Mosley L, Lovato J, Capellari J, Tucker R, Blackstock AW, Miller MS, Miller AA. A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer. J Thorac Oncol. 2007;2(3):197-202.

Petty WJ, Voelzke WR, Memoli VA, Dragnev KH, Urbanic JJ, Rigas JR, Dmitrovsky E. Expression of cyclin D3 confers resistance to erlotinib [abstract]. J Clin Oncol. 2007;25(18 Suppl):Abstr18054.

Hughes AN, O'Brien M, Dunlop D, Petty W, Rankin E, Chick J, Conlan M, Woll P, Nicolson M, Price A. Phase I dose escalation pharmacokinetic study of erlotinib after failure of prior chemotherapy in patients with advanced NSCLC who continue to smoke [abstract]. J Clin Oncol. 2007;25(18 Suppl):161s.

Lally BE, Detterbeck FC, Geiger AM, Thomas CR Jr, Machtay M, Miller AA, Oaks TE, Petty WJ, Robbins ME, Blackstock AW, et al. The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2007;110(4):911-917.

Woll P, Petty WJ, O'Brien M, Rankin E, Dunlop D, Hughes A, Nicolson M, Chick J, Bionpally R, Price A. Randomized phase I pharmacokinetic study of two doses of erlotinib after failure of prior chemotherapy in patients with advanced NSCLC who continue to smoke [abstract]. J Thorac Oncol. 2007;2(8 Suppl 4):S463.

Voelzke WR, Graves JT, Hemphill MB, Gibo DM, Debinski W, Petty WJ, Lesser G. Pre-clinical evaluation of erlotinib and 13-cis-retinoic acid for the treatment of malignant gliomas [abstract]. Neuro Oncol. 2007;9(4):492.

Blackstock AW, Jensen CA, Petty WJ, Oaks T, Porosnicu M, Clark H, Lovato JF, Miller A. Gefitinib (ZD-1839) with concurrent docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel/gefitinib for patients with stage III NSCLC: a phase I study [abstract]. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S476.